There are some, borrowed from the other board-

There are some, borrowed from the other board-

APR-246's success, if it is the first P53 targeting drug on the market, will also be Kevetrin success, provided that Kevetrin keeps showing good results.

Have you ever heard me-too drugs? A new compound gets approved for a lucrative market and immediately about half a dozen drug companies are working on how to circumvent the existing patent. The fastest and usually cheapest way to come up with marketable me-too drug is to buy it. Hence, if Aprea posts successful P3 trial its value will go up and so will IPIXs value, at least in the eyes of the companies wanting their share of P53 market. And it looks like (I am not 100 % certain about this) there is a bonus associated with Kevetrin: who ever might end up with ARP-246 rights in US will have hard time in blocking Kevetrin's entry based on exclusivity - APR-246 and Kevetrin are different chemical entities.

If all goes well with APR-246 it probably will be the first p53 targeting drug on the market. That, however does not guarantee market dominance.